{"id":597781,"date":"2022-04-27T17:36:02","date_gmt":"2022-04-27T17:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=597781"},"modified":"2022-04-27T17:36:02","modified_gmt":"2022-04-27T17:36:02","slug":"fda-lists-modusf-a-new-area-directed-technology-by-stemwave","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fda-lists-modusf-a-new-area-directed-technology-by-stemwave_597781.html","title":{"rendered":"FDA Lists Modus-F, A New Area Directed Technology by StemWave"},"content":{"rendered":"<div style=\"font-style:italic; padding:8px 0px;\">StemWave\u2122 Modus-F is a German-designed medical device<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/4dfe03de005836fd7d2e1f952995324e.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>April 27, 2022 &#8211;<\/strong> FDA lists Modus as a Class l device, with newly developed Area Directed Technology provided by StemWave. StemWave is a Boston-based medical device company focused on developing and introducing innovative orthopedic products.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">StemWave plans to continue the further development of its technology and gain new clearances for Modus over the years to come.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Modus-F is the only Area Directed device available in the United States, creating a large focal zone and in turn, treating more cases.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Despite the significant technological advancements, Modus-F will be introduced at an accessible price point.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About StemWave&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">StemWave is committed to making rehabilitation accessible to the world by developing and introducing revolutionary technology that reshapes traditional healthcare.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/stemwave.com_88945.html\" rel=\"nofollow\">StemWave<\/a><br \/><strong>Contact Person:<\/strong> Helen Baritua<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=fda-lists-modusf-a-new-area-directed-technology-by-stemwave\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 16173951232<br \/><strong>Address:<\/strong>361 Newbury Street  <br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA 02115<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/stemwave.com\/\" target=\"_blank\" rel=\"nofollow\">http:\/\/stemwave.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/stemwave.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=fda-lists-modusf-a-new-area-directed-technology-by-stemwave\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>StemWave\u2122 Modus-F is a German-designed medical device April 27, 2022 &#8211; FDA lists Modus as a Class l device, with newly developed Area Directed Technology provided by StemWave. StemWave is a Boston-based medical device company focused on developing and introducing &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/fda-lists-modusf-a-new-area-directed-technology-by-stemwave_597781.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[408,411,404],"tags":[],"class_list":["post-597781","post","type-post","status-publish","format-standard","hentry","category-Electronics-Semiconductors","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=597781"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597781\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=597781"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=597781"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=597781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}